Skip to main content
Journal cover image

Case definition and phenotype standardization in drug-induced liver injury.

Publication ,  Journal Article
Aithal, GP; Watkins, PB; Andrade, RJ; Larrey, D; Molokhia, M; Takikawa, H; Hunt, CM; Wilke, RA; Avigan, M; Kaplowitz, N; Bjornsson, E; Daly, AK
Published in: Clin Pharmacol Ther
June 2011

Drug-induced liver injury (DILI) is the most frequent reason cited for the withdrawal of approved drugs from the market and accounts for up to 15% of the cases of acute liver failure. Investigators around the globe have begun to identify and study patients with DILI; several large registries and tissue banks are being established. In order to gain the maximum scientific benefit from these efforts, the definitions and terminology related to the clinical phenotypes of DILI must be harmonized. For this purpose, an international DILI Expert Working Group of clinicians and scientists reviewed current DILI terminology and diagnostic criteria so as to develop more uniform criteria that would define and characterize the spectrum of clinical syndromes that constitute DILI. Consensus was established with respect to the threshold criteria for definition of a case as being DILI, the pattern of liver injury, causality assessment, severity, and chronicity. Consensus was also reached on approaches to characterizing DILI in the setting of chronic liver diseases, including autoimmune hepatitis (AIH).

Duke Scholars

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

June 2011

Volume

89

Issue

6

Start / End Page

806 / 815

Location

United States

Related Subject Headings

  • Terminology as Topic
  • Reference Standards
  • Phenotype
  • Pharmacology & Pharmacy
  • Pharmaceutical Preparations
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Diagnosis, Differential
  • Chemical and Drug Induced Liver Injury
  • Animals
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Aithal, G. P., Watkins, P. B., Andrade, R. J., Larrey, D., Molokhia, M., Takikawa, H., … Daly, A. K. (2011). Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther, 89(6), 806–815. https://doi.org/10.1038/clpt.2011.58
Aithal, G. P., P. B. Watkins, R. J. Andrade, D. Larrey, M. Molokhia, H. Takikawa, C. M. Hunt, et al. “Case definition and phenotype standardization in drug-induced liver injury.Clin Pharmacol Ther 89, no. 6 (June 2011): 806–15. https://doi.org/10.1038/clpt.2011.58.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806–15.
Aithal, G. P., et al. “Case definition and phenotype standardization in drug-induced liver injury.Clin Pharmacol Ther, vol. 89, no. 6, June 2011, pp. 806–15. Pubmed, doi:10.1038/clpt.2011.58.
Aithal GP, Watkins PB, Andrade RJ, Larrey D, Molokhia M, Takikawa H, Hunt CM, Wilke RA, Avigan M, Kaplowitz N, Bjornsson E, Daly AK. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther. 2011 Jun;89(6):806–815.
Journal cover image

Published In

Clin Pharmacol Ther

DOI

EISSN

1532-6535

Publication Date

June 2011

Volume

89

Issue

6

Start / End Page

806 / 815

Location

United States

Related Subject Headings

  • Terminology as Topic
  • Reference Standards
  • Phenotype
  • Pharmacology & Pharmacy
  • Pharmaceutical Preparations
  • Humans
  • Drug-Related Side Effects and Adverse Reactions
  • Diagnosis, Differential
  • Chemical and Drug Induced Liver Injury
  • Animals